Xesai
- Clinical-stage biotech company Molecular Partners (NASDAQ:MOLN) and Orano Med, a clinical-stage radiopharmaceutical company expand their strategic collaboration.
- The terms of the new agreement include the development of an additional six targeted alpha therapeutics candidates, now representing a total of ten potential